Treatment guidelines and recommendations for patients treated for chronic myeloid leukaemia (CML) have changed dramatically over the last decade, as a BCR-ABL tyrosine kinase inhibitor (TKI), imatinib, was introduced in 1998 [1,2]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.